skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

ファーマインテリジェンスはInforma PLCのインフォーマインテリジェンス部門の一部です

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon レポートストアメルマガ登録製品ログインProductLogin
Global Search Configuration
  • Close Icon

ジェネリック医薬品、バイオシミラーの情報源として

Generics_Bulletin2

日本国内では2020年9月までにジェネリック医薬品の使用割合を80％にする目標を挙げています。このような中、Generics Bulletinはグローバルな専門アナリスト＆ジャーナリストの広範なネットワークを駆使して、世界中の市場動向を追跡することで、貴重なニュースを提供しています。また、市場プレーヤーのトップエグゼクティブやオピニオンリーダーのインタビューなども定期的に掲載しています。

深い専門性と具体的なデータに基づいたニュースレポートは、世界の大手ジェネリック医薬品メーカーの戦略を明らかにし、その計画、ポートフォリオ、業績を分析＆報告します。

Generics Bulletinでは以下のトピックをカバーしています。

  • 規制・コンプライアンスの変更
  • 法規制の進展
  • 競合製品の開発
  • 合併・買収活動
  • 新製品の発売
  • マーケティングの課題
  • 広告戦略など
無料トライアル申込

このサービスの特徴

世界のジェネリック＆ バイオシミラーを把握

Generics Bulletinの専属ジャーナリストが、ジェネリック医薬品（後発医薬品）、バイオシミラー（バイオ後続品）、付加価値医薬品産業について詳しくお伝えします。

国際競争力を強化する独自のニュースと分析

正確なデータと現地市場のタイムリーな分析により、事実の報道ではない御社の競争力強化に繋がるジェネリック医薬品とバイオシミラー市場の情報をお届けします。

オンラインでアクセスできるから簡単＆便利

スマホ、タブレット、PCなどあらゆるデバイスから記事にアクセスできます。関心のあるニュースやトピックを常に把握できるようにコンテンツのカスタマイズも可能。
ask the expert

ジャーナリスト＆アナ リストがご質問に回答

ニュースや記事の内容又はデータや分析に関してご質問がございましたらお気軽にご連絡下さい。Generics Bulletinのジャーナリストまたはアナリストがお答えします。

無料の最新記事＆レポート

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    EU Sees Drug Shortage Risk From COVID-19 Second Wave

    A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

    Topic Coronavirus Distribution

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

    Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Remdesivir Compulsory Licensing Is A Dead End For Europe

    In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.

    Topic Coronavirus Intellectual Property policy-and-regulation

    View article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Remdesivir Licensing Agreements for Generics Companies

    Keep up with crucial developments in the generics industry as Gilead signs non-exclusive, voluntary licensing agreements with several generics manufacturers in an effort to more widely manufacture and distribute the COVID-19 drug remdesivir, used to help patients recover from severe coronavirus infections faster.

    Topic drug-development-landscape

    Single report

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Glenmark Debuts Favipiravir For COVID-19 In India

    Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.

    Topic Coronavirus Drug Review

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Dr Reddys Joins Remdesivir Licensees

    Dr Reddy’s has become the latest firm to strike a licensing deal with Gilead for its remdesivir potential treatment for COVID-19.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    WHO Launches COVID-19 Technology Access Pool

    C-TAP, the voluntary initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all, has been launched by the WHO, in partnership with Costa Rica.

    Topic Coronavirus

    View article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Teva, Sandoz And Accord Take COVID-19 Action

    While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Hikma Outlines Strategy For Coping With COVID-19 Demand

    Hikma Outlines Strategy For Coping With COVID-19 Demand

    As Hikma launches propofol vials in three presentations in the US to address a local shortage, CEO Siggi Olafsson explains how the company is more broadly keeping on top of the higher demand generated by the coronavirus pandemic.

    Topic Coronavirus

    View article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Teva, Sandoz And Accord Take COVID-19 Action

    While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

    Topic Coronavirus

    View article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    WHO Launches COVID-19 Technology Access Pool

    WHO Launches COVID-19 Technology Access Pool

    C-TAP, the voluntary initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all, has been launched by the WHO, in partnership with Costa Rica.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Celltrion Sets Out Plans To Trial Coronavirus Treatments

    In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Biosimilars Conference Coverage

    Biosimilars Conference Coverage

    Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.

    Topic biosimilars

    Single report

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Celltrion Will Trial COVID-19 Antiviral From July

    Celltrion has made progress in finding an effective treatment for COVID-19 by identifying 14 antibodies able to neutralize coronavirus. The company aims to eventually roll out mass production of a therapeutic antibody treatment after starting human trials this July.

    Topic Coronavirus vaccines

    View article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Australian Bodies Set Out Joint Position On Coronavirus

    Australia’s off-patent industry association, the GBMA, and local brand organization Medicines Australia have set out their plans for collaborating on supplying essential medicines amid the coronavirus pandemic.

    article

医薬品産業専門のジャーナリスト＆アナリスト

Editor

Aidan Fry

Editor, Executive Editor, Commercial/R&D

UK

Aidan Fry

Aidan specializes in

  • Biosimilars
  • Generics
  • Legal Issues And Intellectual Property
  • Market intelligence

+22 year(s) experience

Profile
Consultant

Duncan Emerton

Consultant, Director Pharma Consulting

UK

Duncan Emerton

Duncan specializes in

  • Commercial Strategy
  • Biosimilars
  • Generics

+20 year(s) experience

Profile
Editor

Andrea Charles

Editor, Editor, Custom Content

UK

Andrea Charles

Andrea specializes in

  • Biosimilars
  • Biotech
  • Commercial Strategy
  • Generics
  • Clinical Trials

+17 year(s) experience

Profile
See all analysts

無料トライアル＆お問い合わせ

ニュースサービスでは無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。
Request a free trial

ご質問等ございましたらお気軽にご連絡下さい。

日本（平日：9時～18時）
電話：+81 (0)3 6273 4260
Email：inquiry.jp@informa.com

General enquiry

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。

レポートストア